187 related articles for article (PubMed ID: 36946605)
21. Impact of race on efficacy and safety during treatment with olanzapine in schizophrenia, schizophreniform or schizoaffective disorder.
Stauffer VL; Sniadecki JL; Piezer KW; Gatz J; Kollack-Walker S; Hoffmann VP; Conley R; Durell T
BMC Psychiatry; 2010 Nov; 10():89. PubMed ID: 21047395
[TBL] [Abstract][Full Text] [Related]
22. Change in level of productivity in the treatment of schizophrenia with olanzapine or other antipsychotics.
Liu-Seifert H; Ascher-Svanum H; Osuntokun O; Jen KY; Gomez JC
BMC Psychiatry; 2011 May; 11():87. PubMed ID: 21586165
[TBL] [Abstract][Full Text] [Related]
23. An assessor-blinded, randomized comparison of efficacy and tolerability of switching from olanzapine to ziprasidone and the combination of both in schizophrenia spectrum disorders.
Wang HH; Cai M; Wang HN; Chen YC; Zhang RG; Wang Y; McAlonan GM; Bai YH; Wu WJ; Guo L; Zhang YH; Tan QR; Zhang ZJ
J Psychiatr Res; 2017 Feb; 85():59-65. PubMed ID: 27837658
[TBL] [Abstract][Full Text] [Related]
24. Mitigation of Olanzapine-Induced Weight Gain With Samidorphan, an Opioid Antagonist: A Randomized Double-Blind Phase 2 Study in Patients With Schizophrenia.
Martin WF; Correll CU; Weiden PJ; Jiang Y; Pathak S; DiPetrillo L; Silverman BL; Ehrich EW
Am J Psychiatry; 2019 Jun; 176(6):457-467. PubMed ID: 30845818
[TBL] [Abstract][Full Text] [Related]
25. Olanzapine/Samidorphan: New Drug Approved for Treating Bipolar I Disorder and Schizophrenia.
Monahan C; McCoy L; Powell J; Gums JG
Ann Pharmacother; 2022 Sep; 56(9):1049-1057. PubMed ID: 35040357
[TBL] [Abstract][Full Text] [Related]
26. Samidorphan/olanzapine combination therapy for schizophrenia: Efficacy, tolerance and adverse outcomes of regimen, evidence-based review of clinical trials.
Rehan ST; Siddiqui AH; Khan Z; Imran L; Syed AA; Tahir MJ; Jassani Z; Singh M; Asghar MS; Ahmed A
Ann Med Surg (Lond); 2022 Jul; 79():104115. PubMed ID: 35860157
[TBL] [Abstract][Full Text] [Related]
27. Switching patients with stable schizophrenia or schizoaffective disorder from olanzapine to risperidone long-acting injectable.
Rosa F; Schreiner A; Thomas P; Sherif T
Clin Drug Investig; 2012 Apr; 32(4):267-79. PubMed ID: 22339430
[TBL] [Abstract][Full Text] [Related]
28. Amantadine for weight gain associated with olanzapine treatment.
Deberdt W; Winokur A; Cavazzoni PA; Trzaskoma QN; Carlson CD; Bymaster FP; Wiener K; Floris M; Breier A
Eur Neuropsychopharmacol; 2005 Jan; 15(1):13-21. PubMed ID: 15572269
[TBL] [Abstract][Full Text] [Related]
29. Olanzapine-divalproex combination versus divalproex monotherapy in the treatment of bipolar mixed episodes: a double-blind, placebo-controlled study.
Houston JP; Tohen M; Degenhardt EK; Jamal HH; Liu LL; Ketter TA
J Clin Psychiatry; 2009 Nov; 70(11):1540-7. PubMed ID: 19778495
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of olanzapine for treatment of patients with bipolar depression: Japanese subpopulation analysis of a randomized, double-blind, placebo-controlled study.
Katagiri H; Tohen M; McDonnell DP; Fujikoshi S; Case M; Kanba S; Takahashi M; Gomez JC
BMC Psychiatry; 2013 May; 13():138. PubMed ID: 23672672
[TBL] [Abstract][Full Text] [Related]
31. Randomized, double-blind 6-month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning.
Kinon BJ; Noordsy DL; Liu-Seifert H; Gulliver AH; Ascher-Svanum H; Kollack-Walker S
J Clin Psychopharmacol; 2006 Oct; 26(5):453-61. PubMed ID: 16974184
[TBL] [Abstract][Full Text] [Related]
32. Olanzapine/Samidorphan: A New Combination Treatment for Schizophrenia and Bipolar I Disorder Intended to Reduce Weight Gain.
Corrao MM; Nelson LA
CNS Drugs; 2022 Jun; 36(6):605-616. PubMed ID: 35644903
[TBL] [Abstract][Full Text] [Related]
33. Can an early weight management program (WMP) prevent olanzapine (OLZ)-induced disturbances in body weight, blood glucose and lipid metabolism? Twenty-four- and 48-week results from a 6-month randomized trial.
Cordes J; Thünker J; Regenbrecht G; Zielasek J; Correll CU; Schmidt-Kraepelin C; Lange-Asschenfeldt C; Agelink MW; Kahl KG; Gaebel W; Klimke A; Hauner H
World J Biol Psychiatry; 2014 Apr; 15(3):229-41. PubMed ID: 21745127
[TBL] [Abstract][Full Text] [Related]
34. Early evaluation of patient risk for substantial weight gain during olanzapine treatment for schizophrenia, schizophreniform, or schizoaffective disorder.
Lipkovich I; Jacobson JG; Hardy TA; Hoffmann VP
BMC Psychiatry; 2008 Sep; 8():78. PubMed ID: 18793440
[TBL] [Abstract][Full Text] [Related]
35. Olanzapine versus risperidone in the treatment of manic or mixed States in bipolar I disorder: a randomized, double-blind trial.
Perlis RH; Baker RW; Zarate CA; Brown EB; Schuh LM; Jamal HH; Tohen M
J Clin Psychiatry; 2006 Nov; 67(11):1747-53. PubMed ID: 17196055
[TBL] [Abstract][Full Text] [Related]
36. Ziprasidone vs olanzapine in recent-onset schizophrenia and schizoaffective disorder: results of an 8-week double-blind randomized controlled trial.
Grootens KP; van Veelen NM; Peuskens J; Sabbe BG; Thys E; Buitelaar JK; Verkes RJ; Kahn RS
Schizophr Bull; 2011 Mar; 37(2):352-61. PubMed ID: 19542525
[TBL] [Abstract][Full Text] [Related]
37. Antipsychotic switching versus augmentation among early non-responders to risperidone or olanzapine in acute-phase schizophrenia.
Hatta K; Otachi T; Fujita K; Morikawa F; Ito S; Tomiyama H; Abe T; Sudo Y; Takebayashi H; Yamashita T; Katayama S; Nakase R; Shirai Y; Usui C; Nakamura H; Ito H; Hirata T; Sawa Y;
Schizophr Res; 2014 Sep; 158(1-3):213-22. PubMed ID: 25086659
[TBL] [Abstract][Full Text] [Related]
38. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.
Simpson GM; Glick ID; Weiden PJ; Romano SJ; Siu CO
Am J Psychiatry; 2004 Oct; 161(10):1837-47. PubMed ID: 15465981
[TBL] [Abstract][Full Text] [Related]
39. Olanzapine versus divalproex versus placebo in the treatment of mild to moderate mania: a randomized, 12-week, double-blind study.
Tohen M; Vieta E; Goodwin GM; Sun B; Amsterdam JD; Banov M; Shekhar A; Aaronson ST; Bardenstein L; Grecu-Gabos I; Tochilov V; Prelipceanu D; Oliff HS; Kryzhanovskaya L; Bowden C
J Clin Psychiatry; 2008 Nov; 69(11):1776-89. PubMed ID: 19014751
[TBL] [Abstract][Full Text] [Related]
40. A randomized-controlled trial of blonanserin and olanzapine as adjunct to antipsychotics in the treatment of patients with schizophrenia and dopamine supersensitivity psychosis: The ROADS study.
Niitsu T; Hata T; Nishimoto M; Hosoda Y; Kimura A; Oda Y; Suzuki M; Takase N; Seki R; Fujita K; Endo M; Yoshida T; Inoue M; Hattori N; Murakami T; Imamura Y; Ogawa K; Fukami G; Sato T; Kawasaki Y; Hashimoto T; Ishikawa M; Shiina A; Kanahara N; Iyo M;
Asian J Psychiatr; 2020 Oct; 53():102369. PubMed ID: 32920492
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
